10 Best Aggressive Growth Stocks to Buy According to Wall Street Analysts
On May 13, Reuters reported that Morgan Stanley increased its annual target for the benchmark S&P 500 index.
Beone Medicines Ltd. (ONC)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | HealthInvest Partners AB Anders Hallberg And Carl Bennet | 41,717 | $12,137,163 | +4% | 3.92% |
| 2. | Walleye Capital Will England | 21,051 | $6,251,515 | +616% | 0.03% |
| 3. | Leucadia National Ian Cumming And Joseph Steinberg | 6,200 | $1,841,214 | 0.01% | |
| 4. | Long Corridor Asset Management James Xinjun Tu | 6,020 | $1,787,759 | -23% | 0.43% |
| 5. | 300 | $89,091 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $302.06 | 165,529 | $49,999,938.03 | 18,943,802 | 2021-09-10 | Filing | |
| $108.00 | 5,231,900 | $565,045,200.00 | 5,250,491 | 2018-08-02 | Filing | |
| $108.00 | 582,200 | $62,877,600.00 | 600,791 | 2018-08-02 | Filing | |
| $101.00 | 1,645,148 | $166,159,948.00 | 5,121,404 | 2018-01-18 | Filing | |
| $101.00 | 335,050 | $33,840,050.00 | 708,025 | 2018-01-18 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $311.59 | 332 | $103,447.88 | 0 | 2026-04-08 | Filing | |
| $300.00 | 341 | $102,300.00 | 0 | 2026-03-11 | Filing | |
| $350.00 | 996 | $348,600.00 | 0 | 2026-02-04 | Filing | |
| $348.79 | 664 | $231,596.56 | 996 | 2026-02-04 | Filing | |
| $331.76 | 664 | $220,288.64 | 0 | 2026-01-07 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,975,181 | $1,477,479,502 | 1.16% | |
| 2. | 4,158,726 | $1,231,236,530 | 0.29% | |
| 3. | 1,622,687 | $481,889,358 | 0.07% | |
| 4. | 862,643 | $256,179,092 | 0.84% | |
| 5. | 657,501 | $195,258,096 | 0% |
News See All
8 Most Promising Biotech Stocks to Buy Now
On January 14, Reuters reported that investors foresee a comeback in the US biotech sector in 2026, with more IPO activity and stronger deal-making as legislative risks ease.
7 Fastest Growing European Stocks to Invest In
European stocks are getting a closer look again, and not only because investors want to diversify away from a crowded U.S. trade.
7 Oversold European Stocks to Buy
European equities fell on March 27 while oil prices remained high, as concerns about the impact of conflict in the Middle East persisted despite US President Donald Trump's decision to extend the deadline...
BeOne Medicines (ONC) Reports $1.5B Revenue for Q4, $1.1B from Lymphoma Treatment
On February 26, BeOne Medicines AG (NASDAQ:ONC) reported total global revenues of $1.5 billion for the fourth quarter of 2025 and $5.3 billion for 2026, increases of 33% and 40% from the prior-quarter...
12 Best Stocks to Buy and Hold for the Next 2 Years
Stock performance forecasts from analysts tend to focus on the next quarter or fiscal year, but a report from Citrini Research started a longer-term structural debate.
10 High Growth International Stocks to Buy Now
On February 10, Peter Boockvar, Chief Investment Officer at BFG Wealth Partners, appeared on a CNBC television interview.
Wall Street Bullish on BeOne Medicines AG (ONC) amid Robust Pipeline Development
BeOne Medicines AG (NASDAQ:ONC) is one of the best healthcare stocks to buy for 2026. On January 13, at the 44th Annual J.P.
12 Best Healthcare Stocks to Buy for 2026
Artificial Intelligence has been the catalyst behind the blockbuster rally in equity markets over the past two years.
Citizens Highlights BeOne Medicines’ (ONC) $3.8B Revenue Potential for 2025
BeOne Medicines Ltd. (NASDAQ:ONC) ranks among the best high growth European stocks to buy. On January 7, Citizens reaffirmed its Market Outperform rating and $396 price target for BeOne Medicines Ltd.
Hedge Fund Resource Center